QR-koodi

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic bre...

Täydet tiedot

Tallennettuna:
Päätekijät: Víctor Albarrán, Jesús Chamorro, Javier Pozas, María San Román, Diana Isabel Rosero, Cristina Saavedra, María Gion, Alfonso Cortés, Elena Escalera, Eva Guerra, Elena López Miranda, María Fernández Abad, Noelia Martínez Jañez
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2023-05-01
Sarja:Frontiers in Oncology
Aiheet:
breast cancer
BRCA
germline
PARP inhibitors
olaparib
talazoparib
Linkit:https://www.frontiersin.org/articles/10.3389/fonc.2023.1158981/full
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia